PuraPharm Corporation Limited

HKEX:1498.HK

0.66 (HKD) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2024 Q22023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q22014 Q42014 Q22013 Q4
Revenue 207.627211.778195.081217.309230.76356.835302.757321.383280.432362.321333.558358.899386.604328.473263.093323.737212.249286.998186.902210.746155.60691.588
Cost of Revenue 94.365107.67184.342105.92681.557130.579107.162116.899116.227157.176141.113140.31150.293113.48382.225116.54170.641100.26667.90277.07657.16533.56
Gross Profit 113.262104.107110.739111.383149.203226.256195.595204.484164.205205.145192.445218.589236.311214.99180.868207.196141.608186.732119133.6798.44158.028
Gross Profit Ratio 0.5460.4920.5680.5130.6470.6340.6460.6360.5860.5660.5770.6090.6110.6550.6870.640.6670.6510.6370.6340.6330.634
Reseach & Development Expenses 5.5976.5488.43912.1428.06312.83311.11713.3637.41522.62910.85517.3529.01510.2019.0839.9028.2138.5147.0898.8177.3160
General & Administrative Expenses 75.70890.580.60777.7180.00685.85782.28677.28975.677118.913105.70775.39399.21287.41485.7964.57866.27144.17861.91935.6937.07220.257
Selling & Marketing Expenses 40.20441.48550.17375.02582.358127.56292.444113.76196.778110.356115.856114.016115.979111.14780.60688.88465.49682.22957.98552.18746.98924.794
SG&A 114.648127.934121.201153.542151.339214.258166.025184.644168.145212.955212.397231.83215.191232.344166.396176.614131.767139.686119.90496.14384.06145.051
Other Expenses 0-2.30700000000000000000-1.427-0.968-0.968
Operating Expenses 120.245136.789129.64165.684159.402227.091177.142198.007175.56235.584223.252197.166209.755208.807160.303174.457127.059137.614118.57493.27684.15544.083
Operating Income -6.983-32.682-18.901-54.301-10.199-0.83518.4536.477-11.355-30.439-30.807-11.87521.12-17.35414.47230.5829.84147.046-0.90437.52714.3813.838
Operating Income Ratio -0.034-0.154-0.097-0.25-0.044-0.0020.0610.02-0.04-0.084-0.092-0.0330.055-0.0530.0550.0940.0460.164-0.0050.1780.0920.151
Total Other Income Expenses Net -7.782-33.116-17.613-30.182-24.5-133.743-1.06717.35227.743-142.963-11.94122.714-5.42813.898-0.685-2.3010.545-1.671-4.337-3.32-6.257-3.255
Income Before Tax -14.765-65.798-36.514-84.483-34.699-134.57817.38623.82916.388-173.402-42.74810.83915.692-3.45613.78728.28110.38645.375-5.24134.2078.12310.583
Income Before Tax Ratio -0.071-0.311-0.187-0.389-0.15-0.3770.0570.0740.058-0.479-0.1280.030.041-0.0110.0520.0870.0490.158-0.0280.1620.0520.116
Income Tax Expense 3.9212.6081.161-4.1725.204-0.7275.4123.5564.9518.6762.4323.3812.3443.7934.6494.4042.1019.3212.3556.21.6231.956
Net Income -18.686-68.406-37.675-80.311-39.903-133.85111.97420.27311.437-182.078-45.187.45813.348-7.2499.13823.8778.28536.054-7.59627.9876.4768.627
Net Income Ratio -0.09-0.323-0.193-0.37-0.173-0.3750.040.0630.041-0.503-0.1350.0210.035-0.0220.0350.0740.0390.126-0.0410.1330.0420.094
EPS -0.047-0.17-0.095-0.2-0.1-0.340.030.0520.033-0.66-0.170.030.054-0.030.040.110.0370.16-0.0450.1313.2317.62
EPS Diluted -0.047-0.17-0.095-0.2-0.1-0.340.030.0520.033-0.66-0.170.030.054-0.0290.040.110.0370.16-0.0450.1313.2317.62
EBITDA 4.437-5.4752.483-33.94818.10921.05446.70329.11113.6374.7550.7548.61136.228-3.17925.07537.90317.79752.5076.63544.08521.14117.234
EBITDA Ratio 0.021-0.0260.013-0.1560.0780.0590.1540.0910.0490.0130.0020.0240.094-0.010.0950.1170.0840.1830.0350.2090.1360.188